Skip to content
BALCAO · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP

Yubo International Biotech Ltd. YBGJ

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$12,353
▲ 256.0% YoY
$-1.1M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Yubo Beijing offers its products and services under the brand “VIVCELL.” Yubo Beijing’s product offerings include healthcare products for respiratory system, skincare products, hair care products, healthy beverages and male and female personal care products. Yubo Beijing also offers stem cell related services including cell testing and health management consulting services.

Written from the business description in Yubo International Biotech Limited's annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth

USD 12,353.00
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -1.1
0.5M1.0M-1.0M-2.0M
201020132016201920222025
Compound annual growth
−50.9%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -9614.6% · Net ·
-5000%
201020172025
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF -0.6
-1M-2M
201020172025

Total assetsUSD 847,094.00
EquityUSD -2.0M
CashUSD 8,062.00
DepositsUSD 71,135.00
Current ratio0.24×

Equity funds -231% of total assets.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
YBGJ, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.0◌0.00.00.00.00.00.00.0◌0.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌◌◌◌◌◌◌◌
Income tax $B0.00.00.00.00.00.00.00.00.00.00.0◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌◌◌−0.0−0.00.0◌◌◌◌◌◌◌◌◌◌
EPS, diluted $−0.01−0.02−0.10◌◌◌−0.11−0.13−0.12−0.19−0.11−0.10−0.09−0.09−0.07−0.09
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————————
ROE % — not applicable: negative equity————————————————

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 49 reconciliationsAUDITED

Reconciled in 16 of the 16 fiscal years we could check. 22 checks were skipped: the balance sheet is not tagged before 2018. 13 checks were skipped: cost of revenue is not tagged before 2020. Four checks were skipped: the share count is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onOTC market
Incorporated inNew York
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image